title: Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.
abstract: OBJECTIVE
  To observe the clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  A total of 72 patients were randomly divided into a combination group (pemetrexed+bevacizumab, n=36) and a pemetrexed group (n=36) and assessed for disease control (CR+PR+SD) after 4-cycles of first-line GP chemotherapy (gemcitabine+cisplatin). Clinical efficacy, progression-free survival time (PFS), overall survival time (OS), overall response rate (ORR), disease control rate (DCR) and rate of adverse responses between two groups were observed and compared.
  
  
  RESULTS
  ORR and DCR were 27.8% and 83.4% in combination group, and 16.7% and 69.5% in the pemetrexed group, respectively, but there were no significant differences (P>0.05). PFS in combination group and pemetrexed group were 4.6 months and 3.9 months respectively (P=0.09), whereas OS in the combination group was 14 months, evidently higher than in the pemetrexed group (11 months, P=0.004). Adverse responses in both groups included high blood pressure, bleeding, thrombocytopenia, anemia, elevated transaminase, diarrhea, vomiting and proteinuria, but there were no significant differences (P>0.05).
  
  
  CONCLUSIONS
  Bevacizumab concomitant with pemetrexed has better clinical efficacy and safety, giving rise to prolonged survival time in patients with advanced NSCLC.
authors.affiliation: The Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China E-mail : zhzm05zhzm @163.com.
authors.forename: Yu-Mei
authors.initials: YM
authors.lastname: Zhang
authors.forename: Yong-Qiang
authors.initials: YQ
authors.lastname: Li
authors.forename: Zhi-Hui
authors.initials: ZH
authors.lastname: Liu
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Liao
authors.forename: Rong
authors.initials: R
authors.lastname: Liang
authors.forename: Yan
authors.initials: Y
authors.lastname: Lin
authors.forename: Chun-Ling
authors.initials: CL
authors.lastname: Yuan
authors.forename: Si-Na
authors.initials: SN
authors.lastname: Liao
authors.forename: Chao-Yong
authors.initials: CY
authors.lastname: Liang
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Le-Qun
authors.initials: LQ
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000068437:Pemetrexed; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005971:Glutamates; D000068437:Pemetrexed; D003841:Deoxycytidine; D000068258:Bevacizumab; D006147:Guanine; D002945:Cisplatin; D000093542:Gemcitabine